Market: NMS |
Currency: USD
Address: 427 Park Street
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
📈 Acumen Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.25
-
Upside/Downside from Analyst Target:
266.16%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-12
-
EPS Estimate:
-0.46
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Acumen Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-05-12 (estimated upcoming) | - |
| 2026-03-26 | -0.41 |
| 2025-11-12 | -0.44 |
| 2025-08-12 | -0.68 |
| 2025-05-13 | -0.48 |
| 2025-03-27 | -0.62 |
| 2024-11-12 | -0.5 |
| 2024-08-13 | -0.34 |
| 2024-05-14 | -0.25 |
| 2024-03-26 | -0.29 |
| 2023-11-13 | -0.24 |
| 2023-08-08 | -0.28 |
| 2023-05-09 | -0.28 |
| 2023-03-27 | -0.32 |
| 2022-11-14 | -0.26 |
| 2022-08-15 | -0.25 |
| 2022-05-16 | -0.23 |
| 2022-03-28 | 1.98 |
| 2021-11-15 | -0.1 |
| 2021-08-16 | -7.91 |
📰 Related News & Research
🔍 View more Reports
